Development and validation of risk models for invasive Candida infection
Donald L. Harrison, Kathy Rowan(Intensive Care National Audit & Research Centre), Rosemary A. Barnes(Innsbruck Medical University), H Muskett(Intensive Care National Audit & Research Centre), Mark Jit(London School of Hygiene & Tropical Medicine), C Kibbler(The Royal Free Hospital), Sheila Harvey(St Thomas' Hospital), N. Soni, Elizabeth Allen, Richard Dybowski, Richard Grieve(MRC Clinical Trials Unit at UCL), Jonathan Edgeworth(St Thomas' Hospital), Jason Shahin(McGill University), Kajal Patel, Zia Sadique
Unknown
February 1, 2013
Cited by 0
Related Papers
The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study
|The Lancet Public Health|2020|2.3k
Age-dependent effects in the transmission and control of COVID-19 epidemics
|Nature Medicine|2020|1.9k
Trial of Early, Goal-Directed Resuscitation for Septic Shock
|New England Journal of Medicine|2015|1.6k
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k